- Home
- OXM vs GYRE Comparison
OXM vs GYRE Comparison
Compare OXM & GYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OXM
- GYRE
- Stock Information
- Founded
- OXM 1942
- GYRE 2002
- Country
- OXM United States
- GYRE United States
- Employees
- OXM N/A
- GYRE N/A
- Industry
- OXM Apparel
- GYRE Biotechnology: Pharmaceutical Preparations
- Sector
- OXM Consumer Discretionary
- GYRE Health Care
- Exchange
- OXM Nasdaq
- GYRE Nasdaq
- Market Cap
- OXM 1.4B
- GYRE 1.3B
- IPO Year
- OXM N/A
- GYRE N/A
- Fundamental
- Price
- OXM $77.79
- GYRE $11.29
- Analyst Decision
- OXM Sell
- GYRE
- Analyst Count
- OXM 3
- GYRE 0
- Target Price
- OXM $80.67
- GYRE N/A
- AVG Volume (30 Days)
- OXM 267.2K
- GYRE 65.9K
- Earning Date
- OXM 12-04-2024
- GYRE 11-13-2024
- Dividend Yield
- OXM 3.44%
- GYRE N/A
- EPS Growth
- OXM N/A
- GYRE N/A
- EPS
- OXM 1.89
- GYRE N/A
- Revenue
- OXM $1,549,129,000.00
- GYRE $105,033,000.00
- Revenue This Year
- OXM N/A
- GYRE $25.32
- Revenue Next Year
- OXM $3.31
- GYRE $12.95
- P/E Ratio
- OXM $41.20
- GYRE N/A
- Revenue Growth
- OXM 0.86
- GYRE N/A
- 52 Week Low
- OXM $72.24
- GYRE $8.26
- 52 Week High
- OXM $113.88
- GYRE $30.40
- Technical
- Relative Strength Index (RSI)
- OXM 52.56
- GYRE 32.36
- Support Level
- OXM $73.40
- GYRE $12.33
- Resistance Level
- OXM $80.68
- GYRE $13.24
- Average True Range (ATR)
- OXM 2.37
- GYRE 1.29
- MACD
- OXM 0.22
- GYRE -0.46
- Stochastic Oscillator
- OXM 65.76
- GYRE 2.96
About OXM Oxford Industries Inc.
Oxford Industries Inc is an apparel manufacturing company that designs, sources, markets, and distributes products under the brand name Tommy Bahama, and Lilly Pulitzer. Tommy Bahama designs, sources, markets, and distributes men's and women's sportswear and related products. Lilly Pulitzer designs, sources, markets, and distributes upscale collections of women's and women's dresses, sportswear, and related products. The company generates a majority of its revenue from the Tommy Bahama division.
About GYRE Gyre Therapeutics Inc.
Gyre Therapeutics Inc is a biopharmaceutical company headquartered in San Diego, CA, that is primarily focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis), formerly known as Nonalcoholic Steatohepatitis (NASH)) in the United States. In the United States, Hydronidone is currently being evaluated for the treatment of liver fibrosis across a broad spectrum of chronic liver diseases under an active Investigational New Drug (IND) application. Gyre is also advancing a diverse pipeline in China through a controlling interest in the Beijing Continent, including pirfenidone, F573, F528, and F230.